既往放疗反应与姑息再程放疗后疼痛反应的相关性
本研究基于单中心前瞻性维护观察队列,在病灶层面回顾性分析既往放疗反应与姑息再程放疗后疼痛反应的关系。再程放疗队列纳入148例患者214个病灶,既往有反应者再程放疗后疼痛反应率为60.0%,既往无反应者为15.2%。
要点
- 再程放疗后总体疼痛反应率为43%(93/214个病灶)。
- 既往放疗有反应者再程放疗疼痛反应率60.0%,无反应者仅15.2%。
- 既往无反应人群内部存在异质性,需进一步区分。
核心结论
- 既往放疗反应与姑息再程放疗后疼痛反应强烈相关。
- 既往无反应者再程放疗后疼痛反应率低,提示该人群存在异质性。
研究设计与样本
- 单中心前瞻性维护观察队列的病灶层面回顾性分析。
- 2021年8月至2025年3月筛查800例患者1488个疼痛病灶,排除颅内和术后病灶并限定NRS≥2后,纳入672例患者1125个疼痛病灶。
- 再程放疗队列为148例患者214个病灶,其中既往有反应者63%、既往无反应者37%。
主要发现
- 截至数据截止,455例患者(68%)死亡,中位生存期7.5个月。
- 既往放疗至再程放疗的中位间隔为6.1个月。
- 再程放疗时69%接受单次8 Gy,中位NRS评分为7,77%正在使用阿片类药物。
- 再程放疗后93个病灶(43%)出现疼痛反应。
- 既往有反应者再程放疗后疼痛反应率为60.0%,既往无反应者为15.2%。
关键数值与推荐
- 主要结局为再程放疗后12周内疼痛反应,依据国际共识疼痛反应终点标准评定。
- 疼痛在每次放疗疗程后2、4、12、24、36和52周采用标准化标准评估。
临床怎么用
- 对于既往放疗有反应的复发疼痛病灶,再程放疗可能获得较高的疼痛反应率。
- 对于既往放疗无反应的病灶,再程放疗疼痛反应率较低,决策时需权衡获益。
局限性
- 本研究为单中心回顾性病灶层面分析。
- 再程放疗队列样本量有限(148例患者214个病灶)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pain response to palliative radiotherapy is often temporary; some require re-irradiation. Whether previous radiotherapy response is associated with response to re-irradiation within the same lesions remains unclear. This study compared pain response rates to palliative re-irradiation between patients with previous response and recurrent pain in the same lesion ("previous responders") and those with persistent or progressive pain after non-response to previous radiotherapy ("previous non-responders"). METHODS AND MATERIALS: This retrospective lesion-level analysis was conducted using a prospectively maintained observational cohort at a single cancer center. Patients receiving palliative radiotherapy for painful lesions were followed longitudinally from previous radiotherapy through re-irradiation or death. Between August 2021 and March 2025, 800 patients with 1,488 painful lesions were screened for eligibility. After excluding intracranial and postoperative lesions and limiting the analysis to lesions with an NRS score ≥2, 672 eligible patients with 1,125 painful lesions were included. Pain was assessed at 2, 4, 12, 24, 36, and 52 weeks after each radiotherapy course using standardized criteria. Data were censored on September 30, 2025. The primary outcome was pain response within 12 weeks after re-irradiation, based on the International Consensus Pain Response Endpoints. Secondary outcomes included overall survival and the interval between previous radiotherapy and re-irradiation. RESULTS: By the data cutoff, 455 patients (68%) had died (median survival, 7.5 months). The re-irradiation cohort included 148 patients with 214 lesions; 63% were previous responders and 37% previous non-responders. The median interval from previous radiotherapy to re-irradiation was 6.1 months. At re-irradiation, 69% received single-fraction 8 Gy, the median NRS score was 7, and 77% were receiving opioids. Pain response after re-irradiation was observed in 93 lesions (43%). Response rates differed according to previous radiotherapy response: 60.0% among previous responders versus 15.2% among previous non-responders. CONCLUSIONS: Previous radiotherapy response was strongly associated with pain response after palliative re-irradiation, highlighting the heterogeneity within the previous non-responder population.
引用
- Koide Y, Nimura K, Noguchi M, et al. Association Between Previous Radiotherapy Response and Pain Response After Palliative Re-irradiation. Int J Radiat Oncol Biol Phys. 2026. PMID: 42810414. doi:10.1016/j.ijrobp.2026.06.3098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。